An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness.
about
Advances in understanding and treating ADHDA critical appraisal of atomoxetine in the management of ADHDSystematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety.An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics.An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adultsPharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder.A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.Adolescent D-amphetamine treatment in a rodent model of ADHD: Pro-cognitive effects in adolescence without an impact on cocaine cue reactivity in adulthood.Atomoxetine and stimulant medications in children and adolescents with persistent symptoms of attention deficit hyperactivity disorder despite monotherapy.Performance on a strategy set shifting task during adolescence in a genetic model of attention deficit/hyperactivity disorder: methylphenidate vs. atomoxetine treatmentsPharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: clinical strategiesEfficacy and safety of atomoxetine in the treatment of children and adolescents with attention deficit hyperactivity disorderAtomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review.Combination pharmacotherapy for psychiatric disorders in children and adolescents: prevalence, efficacy, risks and research needs.Background, clinical features and treatment of attention deficit hyperactivity disorder in children.Attention-deficit/hyperactivity disorder with inadequate response to stimulants: approaches to management.A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research.Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review study.Telepsychiatrists' Medication Treatment Strategies in the Children's Attention-Deficit/Hyperactivity Disorder Telemental Health Treatment Study.Acupuncture for attention deficit hyperactivity disorder (ADHD): study protocol for a randomised controlled trial.Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.Differential long-term medication impact on executive function and delay aversion in ADHD.Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder.Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial.
P2860
Q24601949-4D94B26F-1D7E-41A5-9838-AC5E082ED940Q26771187-DE28D7AA-BB37-487C-AD37-65FBDB14539FQ30593927-522907DA-AA25-4AC3-867C-78DB5134316FQ33819929-71675805-A599-4D4E-8F9B-7C5D926C6204Q34220004-07EC40D7-532F-497A-A235-9FD3B367A8C6Q34251275-C52DC8EB-3AD0-4A1D-9791-7B7AB7176420Q34650130-68AB5C6E-F2A3-44DE-B2CD-975179D1CC92Q36372705-B61ADEA8-0728-4DE4-B577-3BAB6A8A028EQ36595998-4AB32E5C-A87F-4F1D-A5B2-FDE1B8B434E1Q36681100-29FC5685-07AE-4EFA-BA1D-CB6408455F62Q36740445-96649B4C-1DE5-4707-9E56-11CE7F18E60FQ36751226-E96A9B10-C60D-4D31-B602-CD7A8FC066F9Q37224562-565B4F24-6E61-4549-8FAD-0B9F7A4D27AAQ38113748-634CA8B4-A2D5-4BFD-87B9-3DECBEB4AA9EQ38122410-5DD5B6DC-F834-4B8C-8ACD-97CA6B00191EQ38176839-00827F00-CA0A-402D-8012-4A24B059546FQ38239633-8179CB11-0FD9-4A44-B191-AE09B56BF608Q38362252-BE62C6D7-691C-42F1-87B8-0C72498F1330Q38613148-53F001FA-809B-4D1B-B639-96CCAE4C2F78Q41646489-878F8067-7377-4A37-9120-395E5294C048Q41768223-593DA6E6-BCCE-4E1C-A1F2-872FCD10DACBQ48308831-D486B58D-2E20-43A6-900F-6A78DA1B6B50Q49821724-68CBA40D-ED18-445A-951B-19864CBD6BA5Q50576718-5D318FA4-A056-4318-9620-DB419A7CCDA5Q50782551-C7F87634-BDBD-4E81-BDE6-4BA37CFB902C
P2860
An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
An open study of adjunct OROS- ...... responders: I. Effectiveness.
@ast
An open study of adjunct OROS- ...... responders: I. Effectiveness.
@en
type
label
An open study of adjunct OROS- ...... responders: I. Effectiveness.
@ast
An open study of adjunct OROS- ...... responders: I. Effectiveness.
@en
prefLabel
An open study of adjunct OROS- ...... responders: I. Effectiveness.
@ast
An open study of adjunct OROS- ...... responders: I. Effectiveness.
@en
P2093
P2860
P356
P1476
An open study of adjunct OROS- ...... responders: I. Effectiveness.
@en
P2093
Anna Georgiopoulous
Kerry Brodziak
Linsey Utzinger
Mary Schillinger
Marykate Martelon
Paul Hammerness
Robert L Doyle
Timothy E Wilens
P2860
P304
P356
10.1089/CAP.2008.0125
P577
2009-10-01T00:00:00Z